AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26087078
Drug: Death-approach language
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Death-approach language (e.g., 'as death closes in on patients')
Trial: 26087078
Drug: Human-approach language
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human-approach language (e.g., 'as patients close in on death')
Trial: 23327232
Drug: Saliva contamination
RxNorm normalized name: Dunaliella salina extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saliva contamination after light polymerization of the bonding agent (group 5)
Trial: 21358561
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clonazepam (1 mg once daily) and Deanxit for 3 weeks
Trial: 21358561
Drug: Clonazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (1 mg once daily) and placebo for 3 weeks
Trial: 17971582
Drug: Two-Dimensional Radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-Dimensional Radiation Therapy (2DRT)
Trial: 15115903
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NTG) 0.5 mg after oral placebo (OP)
Trial: 15115903
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NTG) 0.5 mg after 80 mg isosorbide dinitrate (ISDN)
Trial: 15115903
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NTG) 0.5 mg after 120 mg isosorbide dinitrate (ISDN)
Trial: 15115903
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NTG) after long-term OP therapy
Trial: 15115903
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NTG) after long-term 80 mg ISDN therapy
Trial: 15115903
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NTG) after long-term 120 mg ISDN therapy
Trial: 7272174
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 120 mg
Trial: 15115903
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 80 mg once-daily
Trial: 15115903
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 120 mg once-daily
Trial: 11763107
Drug: Prazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (2 mg t.i.d.)
Trial: 9893926
Drug: Timonil retard
RxNorm normalized name: Timonil Retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timonil retard (test formulation)
Trial: 8061389
Drug: Chemotherapy (5-fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (5-fluorouracil, its analogues, and mitomycin C)
Trial: 947849
Drug: Subunit vaccine
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit vaccine (700 IU)
Trial: 947849
Drug: Subunit vaccine
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit vaccine (2100 IU)
Trial: 947849
Drug: Split vaccine
RxNorm normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split vaccine (800 IU)
Trial: 29064884
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral antibiotics and intravenous antimicrobial prophylaxis
Trial: 29546345
Drug: Multivitamin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin use during treatment
Trial: 29546345
Drug: Other supplement
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other supplement use (before diagnosis or during treatment)
Trial: 25023433
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenous hyoscine-N-butyl bromide (HBB)
Trial: 16643550
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL saline)
Trial: 9586474
Drug: Mk II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mk II self‐tapping implants
Trial: 9586474
Drug: Standard implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard implants
Trial: 31385800
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight iron dextran (1 g)
Trial: 29332050
Drug: Supplemental L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental L (10 mg), MZ (10 mg), and Z (2 mg) daily for 12 months
Trial: 26610430
Drug: Testosterone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (1000 mg T undecanoate)
Trial: 25445074
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for late-life GAD, 10 sessions
Trial: 22245877
Drug: Antimuscarinic agent
RxNorm normalized name: ANTIMUSCARINICS/ANTISPASMODICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinic agent (solifenacin)
Trial: 22245877
Drug: No antimuscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antimuscarinic agent
Trial: 1712835
Drug: Etidronate disodium
RxNorm normalized name: Etidronate Disodium
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate disodium (EHDP) 5 mg/kg/d
Trial: 7040950
Drug: Oral glucose‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose‐electrolyte solution containing 90 mmol of sodium per liter
Trial: 7040950
Drug: Oral glucose‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose‐electrolyte solution containing 50 mmol of sodium per liter
Trial: 10911006
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous therapy
Trial: 22348071
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with EMLA cream
Trial: 2187176
Drug: Survanta (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survanta (100 mg/kg)
Trial: 94008
Drug: Photocoagulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photocoagulation treatment in one eye
Trial: 16527229
Drug: Control eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control eyes (no treatment)
Trial: 31144720
Drug: Antibiotic catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic catheter lead coverage (group A)
Trial: 31144720
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic protection (group B)
Trial: 28724365
Drug: Low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rituximab (500 mg on days 1 and 15)
Trial: 28724365
Drug: Leflunomide (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (10-20 mg/day)
Trial: 23082538
Drug: Buprenorphine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.2 mg/kg s.c.)
Trial: 23082538
Drug: Hydromorphone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (0.5 mg/kg s.c.)
Trial: 23082538
Drug: Buprenorphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.1 mg/kg)
Trial: 23082538
Drug: Buprenorphine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (1 mg/kg)
Trial: 3324596
Drug: Linear incision
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linear incision plus curettage under antibiotic cover
Trial: 20338067
Drug: Purell Instant
RxNorm normalized name: Ethanol 65% Topical application Spray [PURELL INSTANT HAND SANITIZER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purell Instant Hand Sanitizer (1.6 g)
Trial: 20338067
Drug: Alcare plus
RxNorm normalized name: Alcare Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcare plus (1.6 g)
Trial: 20338067
Drug: Water (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (1.6 g)
Trial: 19590518
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intracameral triamcinolone acetonide (TA)
Trial: 18162061
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone acetate 1% eyedrops (6 times per day for 7 days, then 4 times per day for 15 days)
Trial: 12736475
Drug: Class I
RxNorm normalized name: HLA class I antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class I antiarrhythmic drug infusion for 10 min
Trial: 9583853
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for severe malnutrition
Trial: 2119323
Drug: Tolrestat 200
RxNorm normalized name: tolrestat 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolrestat 200 mg once daily
Trial: 8126317
Drug: Methylphenidate (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.6 mg/kg)
Trial: 324389
Drug: Josamycin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josamycin (1.5 g/day)
Trial: 324389
Drug: Erythromycin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1.0 g/day)
Trial: 31808984
Drug: Intramuscular betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular betamethasone
Trial: 25992536
Drug: UPCR weighted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UPCR weighted by estimated daily urine creatinine excretion (eUCr)
Trial: 19702681
Drug: Rough-surface implants
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough-surface implants (TiUnite, n = 45)
Trial: 19702681
Drug: Hybrid surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid surface implants (Restore, n = 45)
Trial: 19702681
Drug: Rough-surface with
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough-surface with microthreads implants (Hexplant, n = 45)
Trial: 11509226
Drug: Ethanol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.8 g/kg, max 60 g males, 50 g females)
Trial: 28663633
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 8 mg with ropivacaine 0.2% (Group B)
Trial: 28663633
Drug: Caudal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ropivacaine 0.2% with dexamethasone 8 mg (Group C)
Trial: 26491204
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical moisturizer during the study period
Trial: 23140912
Drug: FPG ≥126
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG ≥126 mg/dl and HbA1c ≥6.5%
Trial: 19153828
Drug: No endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endocrine treatment (Control)
Trial: 17258182
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment for one year
Trial: 15530262
Drug: Weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly carboplatin (100 mg/m(2))
Trial: 15530262
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose cisplatin (4 mg/m(2))
Trial: 19253522
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker monotherapy
Trial: 9749163
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (75 mg/day)
Trial: 8168557
Drug: Clotrimazole regimen
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole regimen (10 mg twice daily) with Mycostatin (500,000 I.U. four times daily), Benadryl, and Cepacol mouthwash
Trial: 28314838
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate 1,000 mg with prednisone 5 mg twice daily and BEZ235 200 mg twice daily
Trial: 16034044
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen treatment for 2 years
Trial: 16543298
Drug: Assertive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive community treatment team (127 participants)
Trial: 9122104
Drug: Empirical antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antibiotic treatment for suspected pyogenic abscess
Trial: 1362746
Drug: Amoxycillin‐clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin‐clavulanic acid (2.2 g)
Trial: 18426345
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 g)
Trial: 3873345
Drug: Murine antihuman
RxNorm normalized name: Murine Ear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Murine antihuman T-cell monoclonal antibody (mcAb) therapy
Trial: 3873345
Drug: Subsequent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent treatment with ATG after mcAb failure
Trial: 3873345
Drug: Toxicity of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toxicity of mcAb therapy
Trial: 27180107
Drug: Higher NMR
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher NMR (faster nicotine metabolism) in White smokers
Trial: 27180107
Drug: Higher NMR
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher NMR (faster nicotine metabolism) in African American smokers
Trial: 24595629
Drug: intensive glycemia
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intensive glycemia treatment
Trial: 24595629
Drug: intensive BP
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intensive BP treatment
Trial: 24595629
Drug: both intensive
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both intensive glycemia and BP treatment
Trial: 29863695
Drug: Antidepressant +
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant + tranquilizer + antipsychotic agent
Trial: 29863695
Drug: Antidepressant +
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant + tranquilizer
Trial: 29863695
Drug: Antidepressant +
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant + tranquilizer + mood stabilizer
Trial: 22337244
Drug: Sulfasalazine up
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine up to 3 g daily
Trial: 15632821
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (300 mg/d for 2 weeks preoperatively)
Trial: 11773297
Drug: Non-anthracycline-based adjuvant
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-anthracycline-based adjuvant therapies
Trial: 8062524
Drug: Stable isotope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable isotope 54Fe (2.8 mg) given in aqueous form
Trial: 8062524
Drug: Stable isotope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable isotope 54Fe (2.8 mg) taken with a meat meal
Trial: 3302874
Drug: Clavulanic acid-amoxicillin
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clavulanic acid-amoxicillin (ACA)
Trial: 23380178
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate 100 µg twice daily plus placebo tablet once daily
Trial: 23380178
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate 100 µg and salmeterol 50 µg twice daily (combination inhaler) plus placebo tablet once daily
Trial: 23380178
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate 100 µg twice daily plus montelukast 5-mg tablet once daily
Trial: 21979989
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 µg twice daily)
Trial: 16581422
Drug: Subthreshold 810-nm-diode
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subthreshold 810-nm-diode laser treatment
Trial: 9052452
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment for severe peptic ulcer haemorrhage
Trial: 9052452
Drug: Maintenance acid-reducing
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance acid-reducing therapy
Trial: 6669632
Drug: zopiclone 7.5
RxNorm normalized name: zopiclone 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zopiclone 7.5 mg p.o. nightly for 21 days followed by placebo for 7 days
Trial: 26298839
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n=39)
Trial: 25112080
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate tablets (5 mg, 3 times a day for 4 weeks) in western medication control group
Trial: 8787889
Drug: Imipenem plus
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem plus cilastatin (1 g each)
Trial: 7652500
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g)
Trial: 6337495
Drug: Dexamethasone (steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (steroid hormone)
Trial: 30336703
Drug: XR-naltrexone (380
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-naltrexone (380 mg initially, then monthly doses)
Trial: 24002511
Drug: Response-guided chemotherapy
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response-guided chemotherapy (TAC × 8 or TAC-NX)
Trial: 10787067
Drug: Continuous Hyperthermic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Hyperthermic Peritoneal Perfusion (CHPP) with saline solution containing 150 to 300 mg cisplatin and 30 to 60 mg mitomycin C for 60 minutes at 42.0 degrees C (n = 9)
Trial: 10787067
Drug: Continuous Normothermic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Normothermic Peritoneal Perfusion (CNPP) with saline solution containing 150 to 300 mg cisplatin and 30 to 60 mg mitomycin C for 60 minutes at 37.0 degrees C (n = 7)
Trial: 8982739
Drug: Ethinyl oestradiol
RxNorm normalized name: 17-ethinyl-3,17-oestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl oestradiol (50 micrograms daily for 14 days)
Trial: 8982739
Drug: Oestrone sulphate
RxNorm normalized name: Oestrone
DrugBank: Estrone (DB00655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestrone sulphate (2.5 mg daily for 14 days)
Trial: 17434437
Drug: CP‐675,206 immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐675,206 immunotherapy
Trial: 11532477
Drug: Nafarelin acetate
RxNorm normalized name: Nafarelin Acetate
DrugBank: Nafarelin (DB00666)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nafarelin acetate (200 microg b.i.d. for 7 days followed by 200 microg daily)
Trial: 9506565
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of weekly oral methotrexate and daily azathioprine (MTX/AZA)